nodes	percent_of_prediction	percent_of_DWPC	metapath
Dolutegravir—UGT1A1—Estradiol—prostate cancer	0.251	0.605	CbGbCtD
Dolutegravir—UGT1A1—Etoposide—prostate cancer	0.164	0.395	CbGbCtD
Dolutegravir—POU2F2—prostate gland—prostate cancer	0.0281	0.322	CbGeAlD
Dolutegravir—UGT1A1—urine—prostate cancer	0.0236	0.27	CbGeAlD
Dolutegravir—POU2F2—testis—prostate cancer	0.0124	0.142	CbGeAlD
Dolutegravir—POU2F2—lymph node—prostate cancer	0.00896	0.103	CbGeAlD
Dolutegravir—UGT1A1—prostate gland—prostate cancer	0.00847	0.0971	CbGeAlD
Dolutegravir—UGT1A1—renal system—prostate cancer	0.00577	0.0662	CbGeAlD
Dolutegravir—UGT1A1—Estrogen metabolism—CYP1B1—prostate cancer	0.0013	0.00625	CbGpPWpGaD
Dolutegravir—POU2F2—Ectoderm Differentiation—FGFR2—prostate cancer	0.0013	0.00623	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—IL10—prostate cancer	0.00128	0.00615	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—PTEN—prostate cancer	0.00124	0.00595	CbGpPWpGaD
Dolutegravir—UGT1A1—Phase II conjugation—UGT2B15—prostate cancer	0.00121	0.00582	CbGpPWpGaD
Dolutegravir—UGT1A1—Phase II conjugation—UGT2B17—prostate cancer	0.00121	0.00582	CbGpPWpGaD
Dolutegravir—UGT1A1—Constitutive Androstane Receptor Pathway—SULT2A1—prostate cancer	0.00118	0.00569	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—NR3C1—prostate cancer	0.00118	0.00569	CbGpPWpGaD
Dolutegravir—UGT1A1—Phase II conjugation—SULT2B1—prostate cancer	0.00114	0.00548	CbGpPWpGaD
Dolutegravir—UGT1A1—Phase II conjugation—GSTM3—prostate cancer	0.00114	0.00548	CbGpPWpGaD
Dolutegravir—UGT1A1—Estrogen metabolism—COMT—prostate cancer	0.00114	0.00547	CbGpPWpGaD
Dolutegravir—UGT1A1—Phase II conjugation—NAT1—prostate cancer	0.00108	0.00519	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—HIF1A—prostate cancer	0.00108	0.00518	CbGpPWpGaD
Dolutegravir—UGT1A1—Constitutive Androstane Receptor Pathway—CYP2C19—prostate cancer	0.00106	0.00508	CbGpPWpGaD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—GSTA2—prostate cancer	0.00104	0.00501	CbGpPWpGaD
Dolutegravir—UGT1A1—Estrogen metabolism—GSTM1—prostate cancer	0.00104	0.005	CbGpPWpGaD
Dolutegravir—UGT1A1—Constitutive Androstane Receptor Pathway—CYP2A6—prostate cancer	0.00102	0.0049	CbGpPWpGaD
Dolutegravir—UGT1A1—Estrogen metabolism—CYP1A1—prostate cancer	0.000986	0.00474	CbGpPWpGaD
Dolutegravir—UGT1A1—Irinotecan Pathway—APC—prostate cancer	0.000944	0.00454	CbGpPWpGaD
Dolutegravir—UGT1A1—Constitutive Androstane Receptor Pathway—NCOA2—prostate cancer	0.000929	0.00447	CbGpPWpGaD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—AHR—prostate cancer	0.000909	0.00437	CbGpPWpGaD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—NFE2L2—prostate cancer	0.000886	0.00426	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—CREBBP—prostate cancer	0.00088	0.00423	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—PIK3CA—prostate cancer	0.000872	0.00419	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—CBR1—prostate cancer	0.000869	0.00418	CbGpPWpGaD
Dolutegravir—UGT1A1—Constitutive Androstane Receptor Pathway—CYP3A4—prostate cancer	0.000835	0.00402	CbGpPWpGaD
Dolutegravir—UGT1A1—Phase II conjugation—SULT1E1—prostate cancer	0.000818	0.00393	CbGpPWpGaD
Dolutegravir—UGT1A1—Constitutive Androstane Receptor Pathway—NCOA1—prostate cancer	0.000783	0.00377	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—GSTM3—prostate cancer	0.00076	0.00365	CbGpPWpGaD
Dolutegravir—UGT1A1—Constitutive Androstane Receptor Pathway—RXRA—prostate cancer	0.000745	0.00358	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—AKT1—prostate cancer	0.000712	0.00343	CbGpPWpGaD
Dolutegravir—POU2F2—Ectoderm Differentiation—CTNNB1—prostate cancer	0.000712	0.00342	CbGpPWpGaD
Dolutegravir—UGT1A1—Biological oxidations—UGT2B15—prostate cancer	0.000709	0.00341	CbGpPWpGaD
Dolutegravir—UGT1A1—Biological oxidations—UGT2B17—prostate cancer	0.000709	0.00341	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—CXCL8—prostate cancer	0.000699	0.00336	CbGpPWpGaD
Dolutegravir—UGT1A1—Metapathway biotransformation—UGT2B17—prostate cancer	0.000699	0.00336	CbGpPWpGaD
Dolutegravir—UGT1A1—Phase II conjugation—GSTA3—prostate cancer	0.000696	0.00335	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—SLC39A1—prostate cancer	0.000687	0.0033	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—CASP3—prostate cancer	0.000669	0.00322	CbGpPWpGaD
Dolutegravir—UGT1A1—Biological oxidations—SULT2B1—prostate cancer	0.000666	0.0032	CbGpPWpGaD
Dolutegravir—UGT1A1—Biological oxidations—GSTM3—prostate cancer	0.000666	0.0032	CbGpPWpGaD
Dolutegravir—UGT1A1—Metapathway biotransformation—GSTM3—prostate cancer	0.000657	0.00316	CbGpPWpGaD
Dolutegravir—UGT1A1—Metapathway biotransformation—SULT2B1—prostate cancer	0.000657	0.00316	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—CTNNB1—prostate cancer	0.000645	0.0031	CbGpPWpGaD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—NQO1—prostate cancer	0.00064	0.00308	CbGpPWpGaD
Dolutegravir—UGT1A1—Phase II conjugation—GSTA4—prostate cancer	0.000636	0.00306	CbGpPWpGaD
Dolutegravir—UGT1A1—Biological oxidations—CYP3A43—prostate cancer	0.000632	0.00304	CbGpPWpGaD
Dolutegravir—UGT1A1—Biological oxidations—NAT1—prostate cancer	0.000632	0.00304	CbGpPWpGaD
Dolutegravir—UGT1A1—Metapathway biotransformation—CYP3A43—prostate cancer	0.000623	0.003	CbGpPWpGaD
Dolutegravir—UGT1A1—Phase II conjugation—GSTA2—prostate cancer	0.00062	0.00298	CbGpPWpGaD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—CYP1B1—prostate cancer	0.000614	0.00295	CbGpPWpGaD
Dolutegravir—UGT1A1—Phase II conjugation—SULT1A1—prostate cancer	0.000612	0.00295	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—EP300—prostate cancer	0.0006	0.00288	CbGpPWpGaD
Dolutegravir—UGT1A1—Phase II conjugation—GSTA1—prostate cancer	0.000598	0.00288	CbGpPWpGaD
Dolutegravir—UGT1A1—Phase II conjugation—NAT2—prostate cancer	0.000591	0.00284	CbGpPWpGaD
Dolutegravir—UGT1A1—Phase II conjugation—GSTO1—prostate cancer	0.000591	0.00284	CbGpPWpGaD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—NCOA1—prostate cancer	0.000586	0.00282	CbGpPWpGaD
Dolutegravir—POU2F2—Ectoderm Differentiation—MYC—prostate cancer	0.000576	0.00277	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—VEGFA—prostate cancer	0.000568	0.00273	CbGpPWpGaD
Dolutegravir—UGT1A1—Metapathway biotransformation—EPHX1—prostate cancer	0.00053	0.00255	CbGpPWpGaD
Dolutegravir—UGT1A1—Phase II conjugation—SULT2A1—prostate cancer	0.000527	0.00254	CbGpPWpGaD
Dolutegravir—UGT1A1—Biological oxidations—CYP7B1—prostate cancer	0.000491	0.00236	CbGpPWpGaD
Dolutegravir—UGT1A1—Metapathway biotransformation—CYP7B1—prostate cancer	0.000484	0.00233	CbGpPWpGaD
Dolutegravir—UGT1A1—Biological oxidations—SULT1E1—prostate cancer	0.000479	0.0023	CbGpPWpGaD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—BAX—prostate cancer	0.000478	0.0023	CbGpPWpGaD
Dolutegravir—UGT1A1—Phase II conjugation—HPGDS—prostate cancer	0.000473	0.00227	CbGpPWpGaD
Dolutegravir—UGT1A1—Metapathway biotransformation—SULT1E1—prostate cancer	0.000472	0.00227	CbGpPWpGaD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—CYP1A1—prostate cancer	0.000465	0.00224	CbGpPWpGaD
Dolutegravir—Blood bilirubin increased—Doxorubicin—prostate cancer	0.000465	0.00161	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—GSTA3—prostate cancer	0.000464	0.00223	CbGpPWpGaD
Dolutegravir—Blood creatinine increased—Capecitabine—prostate cancer	0.000464	0.0016	CcSEcCtD
Dolutegravir—UGT1A1—Phase II conjugation—GSTT1—prostate cancer	0.000459	0.00221	CbGpPWpGaD
Dolutegravir—Inflammation—Doxorubicin—prostate cancer	0.000453	0.00157	CcSEcCtD
Dolutegravir—Abdominal pain upper—Capecitabine—prostate cancer	0.000452	0.00156	CcSEcCtD
Dolutegravir—Alanine aminotransferase increased—Docetaxel—prostate cancer	0.000451	0.00156	CcSEcCtD
Dolutegravir—Vomiting—Bicalutamide—prostate cancer	0.00045	0.00156	CcSEcCtD
Dolutegravir—Hepatobiliary disease—Etoposide—prostate cancer	0.000448	0.00155	CcSEcCtD
Dolutegravir—Rash—Bicalutamide—prostate cancer	0.000446	0.00154	CcSEcCtD
Dolutegravir—Dermatitis—Bicalutamide—prostate cancer	0.000446	0.00154	CcSEcCtD
Dolutegravir—Insomnia—Goserelin—prostate cancer	0.000445	0.00154	CcSEcCtD
Dolutegravir—Headache—Bicalutamide—prostate cancer	0.000443	0.00153	CcSEcCtD
Dolutegravir—Insomnia—Conjugated Estrogens—prostate cancer	0.000441	0.00152	CcSEcCtD
Dolutegravir—Hypersensitivity—Ethinyl Estradiol—prostate cancer	0.000441	0.00152	CcSEcCtD
Dolutegravir—Alanine aminotransferase increased—Capecitabine—prostate cancer	0.000437	0.00151	CcSEcCtD
Dolutegravir—Abnormal dreams—Doxorubicin—prostate cancer	0.000434	0.0015	CcSEcCtD
Dolutegravir—Rash maculo-papular—Epirubicin—prostate cancer	0.000432	0.00149	CcSEcCtD
Dolutegravir—Vertigo—Estradiol—prostate cancer	0.00043	0.00149	CcSEcCtD
Dolutegravir—Asthenia—Ethinyl Estradiol—prostate cancer	0.000429	0.00148	CcSEcCtD
Dolutegravir—Fatigue—Goserelin—prostate cancer	0.000424	0.00147	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—GSTA4—prostate cancer	0.000424	0.00204	CbGpPWpGaD
Dolutegravir—Pruritus—Ethinyl Estradiol—prostate cancer	0.000423	0.00146	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—CYP3A5—prostate cancer	0.000421	0.00203	CbGpPWpGaD
Dolutegravir—Gastrointestinal disorder—Conjugated Estrogens—prostate cancer	0.000421	0.00146	CcSEcCtD
Dolutegravir—Urinary tract disorder—Etoposide—prostate cancer	0.00042	0.00145	CcSEcCtD
Dolutegravir—Fatigue—Conjugated Estrogens—prostate cancer	0.00042	0.00145	CcSEcCtD
Dolutegravir—Nausea—Bicalutamide—prostate cancer	0.00042	0.00145	CcSEcCtD
Dolutegravir—Urethral disorder—Etoposide—prostate cancer	0.000417	0.00144	CcSEcCtD
Dolutegravir—UGT1A1—Metapathway biotransformation—CYP3A5—prostate cancer	0.000416	0.002	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—GSTA2—prostate cancer	0.000414	0.00199	CbGpPWpGaD
Dolutegravir—Neutropenia—Docetaxel—prostate cancer	0.000413	0.00143	CcSEcCtD
Dolutegravir—Abdominal discomfort—Capecitabine—prostate cancer	0.00041	0.00142	CcSEcCtD
Dolutegravir—Diarrhoea—Ethinyl Estradiol—prostate cancer	0.000409	0.00141	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—GSTA3—prostate cancer	0.000407	0.00196	CbGpPWpGaD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Estradiol—prostate cancer	0.000404	0.0014	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Goserelin—prostate cancer	0.000402	0.00139	CcSEcCtD
Dolutegravir—UGT1A1—Metapathway biotransformation—GSTA3—prostate cancer	0.000401	0.00193	CbGpPWpGaD
Dolutegravir—Neutropenia—Capecitabine—prostate cancer	0.0004	0.00138	CcSEcCtD
Dolutegravir—Rash maculo-papular—Doxorubicin—prostate cancer	0.0004	0.00138	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—GSTA1—prostate cancer	0.000399	0.00192	CbGpPWpGaD
Dolutegravir—Gastrointestinal pain—Conjugated Estrogens—prostate cancer	0.000399	0.00138	CcSEcCtD
Dolutegravir—Dizziness—Ethinyl Estradiol—prostate cancer	0.000395	0.00137	CcSEcCtD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—IL6—prostate cancer	0.000393	0.00189	CbGpPWpGaD
Dolutegravir—Abdominal pain—Goserelin—prostate cancer	0.000389	0.00135	CcSEcCtD
Dolutegravir—Alanine aminotransferase increased—Prednisone—prostate cancer	0.000389	0.00134	CcSEcCtD
Dolutegravir—Renal failure—Docetaxel—prostate cancer	0.000387	0.00134	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—HSP90AB1—prostate cancer	0.000386	0.00186	CbGpPWpGaD
Dolutegravir—Hyperglycaemia—Capecitabine—prostate cancer	0.000386	0.00133	CcSEcCtD
Dolutegravir—Abdominal pain—Conjugated Estrogens—prostate cancer	0.000385	0.00133	CcSEcCtD
Dolutegravir—Immune system disorder—Etoposide—prostate cancer	0.000384	0.00133	CcSEcCtD
Dolutegravir—Nervous system disorder—Estradiol—prostate cancer	0.000383	0.00132	CcSEcCtD
Dolutegravir—Vomiting—Ethinyl Estradiol—prostate cancer	0.00038	0.00131	CcSEcCtD
Dolutegravir—Skin disorder—Estradiol—prostate cancer	0.000379	0.00131	CcSEcCtD
Dolutegravir—Rash—Ethinyl Estradiol—prostate cancer	0.000377	0.0013	CcSEcCtD
Dolutegravir—Dermatitis—Ethinyl Estradiol—prostate cancer	0.000377	0.0013	CcSEcCtD
Dolutegravir—Renal failure—Capecitabine—prostate cancer	0.000375	0.0013	CcSEcCtD
Dolutegravir—Headache—Ethinyl Estradiol—prostate cancer	0.000375	0.0013	CcSEcCtD
Dolutegravir—Hepatobiliary disease—Docetaxel—prostate cancer	0.000373	0.00129	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—GSTA4—prostate cancer	0.000372	0.00179	CbGpPWpGaD
Dolutegravir—UGT1A1—Biological oxidations—TBXAS1—prostate cancer	0.000372	0.00179	CbGpPWpGaD
Dolutegravir—UGT1A1—Metapathway biotransformation—GSTA4—prostate cancer	0.000367	0.00177	CbGpPWpGaD
Dolutegravir—UGT1A1—Biological oxidations—GSTA2—prostate cancer	0.000363	0.00174	CbGpPWpGaD
Dolutegravir—Hypersensitivity—Goserelin—prostate cancer	0.000363	0.00125	CcSEcCtD
Dolutegravir—Renal impairment—Epirubicin—prostate cancer	0.000362	0.00125	CcSEcCtD
Dolutegravir—Hepatobiliary disease—Capecitabine—prostate cancer	0.000361	0.00125	CcSEcCtD
Dolutegravir—Hypersensitivity—Conjugated Estrogens—prostate cancer	0.000359	0.00124	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—SULT1A1—prostate cancer	0.000358	0.00172	CbGpPWpGaD
Dolutegravir—Neutropenia—Prednisone—prostate cancer	0.000356	0.00123	CcSEcCtD
Dolutegravir—Nausea—Ethinyl Estradiol—prostate cancer	0.000355	0.00123	CcSEcCtD
Dolutegravir—UGT1A1—Phase II conjugation—GGT1—prostate cancer	0.000354	0.0017	CbGpPWpGaD
Dolutegravir—Hepatitis—Docetaxel—prostate cancer	0.000354	0.00122	CcSEcCtD
Dolutegravir—UGT1A1—Metapathway biotransformation—SULT1A1—prostate cancer	0.000353	0.0017	CbGpPWpGaD
Dolutegravir—Asthenia—Goserelin—prostate cancer	0.000353	0.00122	CcSEcCtD
Dolutegravir—Skin disorder—Mitoxantrone—prostate cancer	0.000353	0.00122	CcSEcCtD
Dolutegravir—Insomnia—Estradiol—prostate cancer	0.000353	0.00122	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—NFE2L2—prostate cancer	0.000352	0.00169	CbGpPWpGaD
Dolutegravir—UGT1A1—Biological oxidations—GSTA1—prostate cancer	0.00035	0.00168	CbGpPWpGaD
Dolutegravir—Asthenia—Conjugated Estrogens—prostate cancer	0.00035	0.00121	CcSEcCtD
Dolutegravir—Urinary tract disorder—Docetaxel—prostate cancer	0.000349	0.00121	CcSEcCtD
Dolutegravir—Pruritus—Goserelin—prostate cancer	0.000348	0.0012	CcSEcCtD
Dolutegravir—Urethral disorder—Docetaxel—prostate cancer	0.000347	0.0012	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—GSTO1—prostate cancer	0.000346	0.00166	CbGpPWpGaD
Dolutegravir—UGT1A1—Biological oxidations—NAT2—prostate cancer	0.000346	0.00166	CbGpPWpGaD
Dolutegravir—Pruritus—Conjugated Estrogens—prostate cancer	0.000345	0.00119	CcSEcCtD
Dolutegravir—Hyperglycaemia—Prednisone—prostate cancer	0.000344	0.00119	CcSEcCtD
Dolutegravir—Hepatitis—Capecitabine—prostate cancer	0.000343	0.00118	CcSEcCtD
Dolutegravir—UGT1A1—Metapathway biotransformation—GSTO1—prostate cancer	0.000341	0.00164	CbGpPWpGaD
Dolutegravir—UGT1A1—Metapathway biotransformation—NAT2—prostate cancer	0.000341	0.00164	CbGpPWpGaD
Dolutegravir—Urinary tract disorder—Capecitabine—prostate cancer	0.000338	0.00117	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Estradiol—prostate cancer	0.000337	0.00116	CcSEcCtD
Dolutegravir—Diarrhoea—Goserelin—prostate cancer	0.000337	0.00116	CcSEcCtD
Dolutegravir—Fatigue—Estradiol—prostate cancer	0.000336	0.00116	CcSEcCtD
Dolutegravir—Urethral disorder—Capecitabine—prostate cancer	0.000336	0.00116	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—TGFA—prostate cancer	0.000335	0.00161	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—GPX3—prostate cancer	0.000335	0.00161	CbGpPWpGaD
Dolutegravir—Renal impairment—Doxorubicin—prostate cancer	0.000335	0.00116	CcSEcCtD
Dolutegravir—Diarrhoea—Conjugated Estrogens—prostate cancer	0.000334	0.00115	CcSEcCtD
Dolutegravir—Vertigo—Etoposide—prostate cancer	0.000333	0.00115	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—CYP2C18—prostate cancer	0.000332	0.0016	CbGpPWpGaD
Dolutegravir—UGT1A1—Metapathway biotransformation—CYP2C18—prostate cancer	0.000327	0.00157	CbGpPWpGaD
Dolutegravir—Dizziness—Goserelin—prostate cancer	0.000325	0.00113	CcSEcCtD
Dolutegravir—Blood creatinine increased—Epirubicin—prostate cancer	0.000323	0.00112	CcSEcCtD
Dolutegravir—Dizziness—Conjugated Estrogens—prostate cancer	0.000322	0.00111	CcSEcCtD
Dolutegravir—Immune system disorder—Docetaxel—prostate cancer	0.00032	0.0011	CcSEcCtD
Dolutegravir—UGT1A1—Phase II conjugation—COMT—prostate cancer	0.000319	0.00154	CbGpPWpGaD
Dolutegravir—Gastrointestinal pain—Estradiol—prostate cancer	0.000319	0.0011	CcSEcCtD
Dolutegravir—UGT1A1—Phase II conjugation—GSTP1—prostate cancer	0.000318	0.00153	CbGpPWpGaD
Dolutegravir—Abdominal pain upper—Epirubicin—prostate cancer	0.000315	0.00109	CcSEcCtD
Dolutegravir—Fatigue—Mitoxantrone—prostate cancer	0.000313	0.00108	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Etoposide—prostate cancer	0.000313	0.00108	CcSEcCtD
Dolutegravir—Vomiting—Goserelin—prostate cancer	0.000313	0.00108	CcSEcCtD
Dolutegravir—Rash—Goserelin—prostate cancer	0.00031	0.00107	CcSEcCtD
Dolutegravir—Dermatitis—Goserelin—prostate cancer	0.00031	0.00107	CcSEcCtD
Dolutegravir—Vomiting—Conjugated Estrogens—prostate cancer	0.00031	0.00107	CcSEcCtD
Dolutegravir—Mental disorder—Docetaxel—prostate cancer	0.00031	0.00107	CcSEcCtD
Dolutegravir—Immune system disorder—Capecitabine—prostate cancer	0.000309	0.00107	CcSEcCtD
Dolutegravir—Abdominal pain—Estradiol—prostate cancer	0.000308	0.00107	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—SULT2A1—prostate cancer	0.000308	0.00148	CbGpPWpGaD
Dolutegravir—Headache—Goserelin—prostate cancer	0.000308	0.00107	CcSEcCtD
Dolutegravir—Rash—Conjugated Estrogens—prostate cancer	0.000307	0.00106	CcSEcCtD
Dolutegravir—Dermatitis—Conjugated Estrogens—prostate cancer	0.000307	0.00106	CcSEcCtD
Dolutegravir—Headache—Conjugated Estrogens—prostate cancer	0.000305	0.00106	CcSEcCtD
Dolutegravir—Alanine aminotransferase increased—Epirubicin—prostate cancer	0.000304	0.00105	CcSEcCtD
Dolutegravir—UGT1A1—Metapathway biotransformation—SULT2A1—prostate cancer	0.000304	0.00146	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—CYP2A6—prostate cancer	0.000302	0.00145	CbGpPWpGaD
Dolutegravir—Mental disorder—Capecitabine—prostate cancer	0.0003	0.00104	CcSEcCtD
Dolutegravir—Blood creatinine increased—Doxorubicin—prostate cancer	0.000299	0.00103	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Mitoxantrone—prostate cancer	0.000297	0.00103	CcSEcCtD
Dolutegravir—Flatulence—Capecitabine—prostate cancer	0.000294	0.00102	CcSEcCtD
Dolutegravir—Skin disorder—Etoposide—prostate cancer	0.000294	0.00102	CcSEcCtD
Dolutegravir—Nausea—Goserelin—prostate cancer	0.000292	0.00101	CcSEcCtD
Dolutegravir—UGT1A1—Phase II conjugation—GSTM1—prostate cancer	0.000292	0.0014	CbGpPWpGaD
Dolutegravir—Abdominal pain upper—Doxorubicin—prostate cancer	0.000291	0.00101	CcSEcCtD
Dolutegravir—UGT1A1—Metapathway biotransformation—GPX3—prostate cancer	0.00029	0.0014	CbGpPWpGaD
Dolutegravir—Nausea—Conjugated Estrogens—prostate cancer	0.00029	0.001	CcSEcCtD
Dolutegravir—Hypersensitivity—Estradiol—prostate cancer	0.000287	0.000994	CcSEcCtD
Dolutegravir—Abdominal pain—Mitoxantrone—prostate cancer	0.000287	0.000994	CcSEcCtD
Dolutegravir—Alanine aminotransferase increased—Doxorubicin—prostate cancer	0.000281	0.000973	CcSEcCtD
Dolutegravir—Asthenia—Estradiol—prostate cancer	0.00028	0.000968	CcSEcCtD
Dolutegravir—Neutropenia—Epirubicin—prostate cancer	0.000279	0.000964	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—HPGDS—prostate cancer	0.000277	0.00133	CbGpPWpGaD
Dolutegravir—Pruritus—Estradiol—prostate cancer	0.000276	0.000954	CcSEcCtD
Dolutegravir—Immune system disorder—Prednisone—prostate cancer	0.000276	0.000953	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—CYP2C19—prostate cancer	0.000275	0.00132	CbGpPWpGaD
Dolutegravir—UGT1A1—Metapathway biotransformation—CYP2C19—prostate cancer	0.000271	0.0013	CbGpPWpGaD
Dolutegravir—Hyperglycaemia—Epirubicin—prostate cancer	0.000269	0.00093	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—GSTT1—prostate cancer	0.000268	0.00129	CbGpPWpGaD
Dolutegravir—Vertigo—Capecitabine—prostate cancer	0.000268	0.000926	CcSEcCtD
Dolutegravir—Hypersensitivity—Mitoxantrone—prostate cancer	0.000268	0.000926	CcSEcCtD
Dolutegravir—Mental disorder—Prednisone—prostate cancer	0.000267	0.000924	CcSEcCtD
Dolutegravir—Diarrhoea—Estradiol—prostate cancer	0.000267	0.000923	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—CYP2A6—prostate cancer	0.000265	0.00128	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—SLC5A5—prostate cancer	0.000263	0.00127	CbGpPWpGaD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—CDKN1B—prostate cancer	0.000262	0.00126	CbGpPWpGaD
Dolutegravir—Renal failure—Epirubicin—prostate cancer	0.000261	0.000903	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Etoposide—prostate cancer	0.000261	0.000903	CcSEcCtD
Dolutegravir—Asthenia—Mitoxantrone—prostate cancer	0.000261	0.000902	CcSEcCtD
Dolutegravir—Fatigue—Etoposide—prostate cancer	0.000261	0.000901	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	0.00026	0.0009	CcSEcCtD
Dolutegravir—Dizziness—Estradiol—prostate cancer	0.000258	0.000892	CcSEcCtD
Dolutegravir—Neutropenia—Doxorubicin—prostate cancer	0.000258	0.000892	CcSEcCtD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL2—prostate cancer	0.000256	0.00123	CbGpPWpGaD
Dolutegravir—UGT1A1—Metapathway biotransformation—AKR1C3—prostate cancer	0.000254	0.00122	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—NQO1—prostate cancer	0.000254	0.00122	CbGpPWpGaD
Dolutegravir—UGT1A1—Biological oxidations—CYP17A1—prostate cancer	0.000254	0.00122	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—HSPA1A—prostate cancer	0.000252	0.00121	CbGpPWpGaD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	0.000252	0.000872	CcSEcCtD
Dolutegravir—Hepatobiliary disease—Epirubicin—prostate cancer	0.000251	0.000869	CcSEcCtD
Dolutegravir—UGT1A1—Metapathway biotransformation—CYP17A1—prostate cancer	0.00025	0.0012	CbGpPWpGaD
Dolutegravir—Hyperglycaemia—Doxorubicin—prostate cancer	0.000249	0.00086	CcSEcCtD
Dolutegravir—Diarrhoea—Mitoxantrone—prostate cancer	0.000249	0.00086	CcSEcCtD
Dolutegravir—Vomiting—Estradiol—prostate cancer	0.000248	0.000858	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Etoposide—prostate cancer	0.000247	0.000855	CcSEcCtD
Dolutegravir—Nervous system disorder—Docetaxel—prostate cancer	0.000246	0.000852	CcSEcCtD
Dolutegravir—Rash—Estradiol—prostate cancer	0.000246	0.000851	CcSEcCtD
Dolutegravir—Dermatitis—Estradiol—prostate cancer	0.000246	0.00085	CcSEcCtD
Dolutegravir—Headache—Estradiol—prostate cancer	0.000244	0.000845	CcSEcCtD
Dolutegravir—Skin disorder—Docetaxel—prostate cancer	0.000244	0.000844	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—NCOA2—prostate cancer	0.000242	0.00116	CbGpPWpGaD
Dolutegravir—Renal failure—Doxorubicin—prostate cancer	0.000242	0.000836	CcSEcCtD
Dolutegravir—Abdominal pain—Etoposide—prostate cancer	0.000239	0.000827	CcSEcCtD
Dolutegravir—Nervous system disorder—Capecitabine—prostate cancer	0.000239	0.000825	CcSEcCtD
Dolutegravir—Vertigo—Prednisone—prostate cancer	0.000239	0.000825	CcSEcCtD
Dolutegravir—Hepatitis—Epirubicin—prostate cancer	0.000239	0.000825	CcSEcCtD
Dolutegravir—Skin disorder—Capecitabine—prostate cancer	0.000236	0.000817	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—EGR1—prostate cancer	0.000236	0.00114	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—GGT1—prostate cancer	0.000236	0.00114	CbGpPWpGaD
Dolutegravir—Urinary tract disorder—Epirubicin—prostate cancer	0.000236	0.000815	CcSEcCtD
Dolutegravir—Urethral disorder—Epirubicin—prostate cancer	0.000234	0.000809	CcSEcCtD
Dolutegravir—Hepatobiliary disease—Doxorubicin—prostate cancer	0.000233	0.000804	CcSEcCtD
Dolutegravir—Nausea—Estradiol—prostate cancer	0.000232	0.000801	CcSEcCtD
Dolutegravir—Vomiting—Mitoxantrone—prostate cancer	0.000231	0.000799	CcSEcCtD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EP300—prostate cancer	0.00023	0.00111	CbGpPWpGaD
Dolutegravir—Rash—Mitoxantrone—prostate cancer	0.000229	0.000793	CcSEcCtD
Dolutegravir—Dermatitis—Mitoxantrone—prostate cancer	0.000229	0.000792	CcSEcCtD
Dolutegravir—Headache—Mitoxantrone—prostate cancer	0.000228	0.000787	CcSEcCtD
Dolutegravir—Insomnia—Docetaxel—prostate cancer	0.000227	0.000786	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—CYP2E1—prostate cancer	0.000226	0.00108	CbGpPWpGaD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	0.000225	0.000776	CcSEcCtD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—SRC—prostate cancer	0.000224	0.00108	CbGpPWpGaD
Dolutegravir—Hypersensitivity—Etoposide—prostate cancer	0.000223	0.00077	CcSEcCtD
Dolutegravir—UGT1A1—Metapathway biotransformation—CYP2E1—prostate cancer	0.000222	0.00107	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—RXRA—prostate cancer	0.000221	0.00106	CbGpPWpGaD
Dolutegravir—Hepatitis—Doxorubicin—prostate cancer	0.000221	0.000763	CcSEcCtD
Dolutegravir—Insomnia—Capecitabine—prostate cancer	0.00022	0.000761	CcSEcCtD
Dolutegravir—Urinary tract disorder—Doxorubicin—prostate cancer	0.000218	0.000754	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—CYP3A4—prostate cancer	0.000217	0.00105	CbGpPWpGaD
Dolutegravir—Gastrointestinal disorder—Docetaxel—prostate cancer	0.000217	0.00075	CcSEcCtD
Dolutegravir—Asthenia—Etoposide—prostate cancer	0.000217	0.00075	CcSEcCtD
Dolutegravir—Fatigue—Docetaxel—prostate cancer	0.000217	0.000749	CcSEcCtD
Dolutegravir—Urethral disorder—Doxorubicin—prostate cancer	0.000216	0.000748	CcSEcCtD
Dolutegravir—Nausea—Mitoxantrone—prostate cancer	0.000216	0.000747	CcSEcCtD
Dolutegravir—Immune system disorder—Epirubicin—prostate cancer	0.000216	0.000745	CcSEcCtD
Dolutegravir—UGT1A1—Metapathway biotransformation—CYP3A4—prostate cancer	0.000214	0.00103	CbGpPWpGaD
Dolutegravir—Pruritus—Etoposide—prostate cancer	0.000214	0.00074	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—CYP1B1—prostate cancer	0.000214	0.00103	CbGpPWpGaD
Dolutegravir—Nervous system disorder—Prednisone—prostate cancer	0.000213	0.000735	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—GSTP1—prostate cancer	0.000212	0.00102	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—TGFBR2—prostate cancer	0.000212	0.00102	CbGpPWpGaD
Dolutegravir—UGT1A1—Metapathway biotransformation—CYP1B1—prostate cancer	0.000211	0.00101	CbGpPWpGaD
Dolutegravir—Skin disorder—Prednisone—prostate cancer	0.000211	0.000728	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Capecitabine—prostate cancer	0.00021	0.000726	CcSEcCtD
Dolutegravir—Fatigue—Capecitabine—prostate cancer	0.00021	0.000725	CcSEcCtD
Dolutegravir—Mental disorder—Epirubicin—prostate cancer	0.000209	0.000723	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—GGT1—prostate cancer	0.000207	0.000996	CbGpPWpGaD
Dolutegravir—Diarrhoea—Etoposide—prostate cancer	0.000207	0.000715	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Docetaxel—prostate cancer	0.000206	0.000711	CcSEcCtD
Dolutegravir—Flatulence—Epirubicin—prostate cancer	0.000205	0.000708	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—NCOA1—prostate cancer	0.000204	0.000981	CbGpPWpGaD
Dolutegravir—UGT1A1—Biological oxidations—CYP19A1—prostate cancer	0.000201	0.000967	CbGpPWpGaD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TGFB1—prostate cancer	0.0002	0.000962	CbGpPWpGaD
Dolutegravir—Dizziness—Etoposide—prostate cancer	0.0002	0.000691	CcSEcCtD
Dolutegravir—Immune system disorder—Doxorubicin—prostate cancer	0.000199	0.000689	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Capecitabine—prostate cancer	0.000199	0.000688	CcSEcCtD
Dolutegravir—Abdominal pain—Docetaxel—prostate cancer	0.000199	0.000687	CcSEcCtD
Dolutegravir—UGT1A1—Metapathway biotransformation—CYP19A1—prostate cancer	0.000198	0.000953	CbGpPWpGaD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—prostate cancer	0.000196	0.000943	CbGpPWpGaD
Dolutegravir—Insomnia—Prednisone—prostate cancer	0.000196	0.000678	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—GSTM1—prostate cancer	0.000195	0.000937	CbGpPWpGaD
Dolutegravir—UGT1A1—Biological oxidations—RXRA—prostate cancer	0.000194	0.000933	CbGpPWpGaD
Dolutegravir—Mental disorder—Doxorubicin—prostate cancer	0.000193	0.000669	CcSEcCtD
Dolutegravir—Abdominal pain—Capecitabine—prostate cancer	0.000192	0.000665	CcSEcCtD
Dolutegravir—Vomiting—Etoposide—prostate cancer	0.000192	0.000665	CcSEcCtD
Dolutegravir—Rash—Etoposide—prostate cancer	0.000191	0.000659	CcSEcCtD
Dolutegravir—Dermatitis—Etoposide—prostate cancer	0.000191	0.000659	CcSEcCtD
Dolutegravir—Headache—Etoposide—prostate cancer	0.000189	0.000655	CcSEcCtD
Dolutegravir—Flatulence—Doxorubicin—prostate cancer	0.000189	0.000655	CcSEcCtD
Dolutegravir—Fatigue—Prednisone—prostate cancer	0.000187	0.000646	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—COMT—prostate cancer	0.000187	0.000899	CbGpPWpGaD
Dolutegravir—Vertigo—Epirubicin—prostate cancer	0.000187	0.000645	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—GSTP1—prostate cancer	0.000186	0.000894	CbGpPWpGaD
Dolutegravir—Hypersensitivity—Docetaxel—prostate cancer	0.000185	0.00064	CcSEcCtD
Dolutegravir—UGT1A1—Metapathway biotransformation—COMT—prostate cancer	0.000184	0.000886	CbGpPWpGaD
Dolutegravir—UGT1A1—Metapathway biotransformation—GSTP1—prostate cancer	0.000183	0.000882	CbGpPWpGaD
Dolutegravir—Asthenia—Docetaxel—prostate cancer	0.00018	0.000623	CcSEcCtD
Dolutegravir—Nausea—Etoposide—prostate cancer	0.00018	0.000621	CcSEcCtD
Dolutegravir—Hypersensitivity—Capecitabine—prostate cancer	0.000179	0.00062	CcSEcCtD
Dolutegravir—Pruritus—Docetaxel—prostate cancer	0.000178	0.000615	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Prednisone—prostate cancer	0.000177	0.000613	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	0.000176	0.000607	CcSEcCtD
Dolutegravir—Asthenia—Capecitabine—prostate cancer	0.000175	0.000604	CcSEcCtD
Dolutegravir—Vertigo—Doxorubicin—prostate cancer	0.000173	0.000597	CcSEcCtD
Dolutegravir—Pruritus—Capecitabine—prostate cancer	0.000172	0.000595	CcSEcCtD
Dolutegravir—Diarrhoea—Docetaxel—prostate cancer	0.000172	0.000595	CcSEcCtD
Dolutegravir—Abdominal pain—Prednisone—prostate cancer	0.000171	0.000592	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—GSTM1—prostate cancer	0.000171	0.000822	CbGpPWpGaD
Dolutegravir—UGT1A1—Metapathway biotransformation—GSTM1—prostate cancer	0.000169	0.000811	CbGpPWpGaD
Dolutegravir—Diarrhoea—Capecitabine—prostate cancer	0.000166	0.000576	CcSEcCtD
Dolutegravir—Nervous system disorder—Epirubicin—prostate cancer	0.000166	0.000575	CcSEcCtD
Dolutegravir—Dizziness—Docetaxel—prostate cancer	0.000166	0.000575	CcSEcCtD
Dolutegravir—Skin disorder—Epirubicin—prostate cancer	0.000165	0.000569	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	0.000162	0.000562	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—CYP1A1—prostate cancer	0.000162	0.000779	CbGpPWpGaD
Dolutegravir—Dizziness—Capecitabine—prostate cancer	0.000161	0.000556	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—HAO1—prostate cancer	0.00016	0.000769	CbGpPWpGaD
Dolutegravir—Vomiting—Docetaxel—prostate cancer	0.00016	0.000552	CcSEcCtD
Dolutegravir—UGT1A1—Metapathway biotransformation—CYP1A1—prostate cancer	0.00016	0.000768	CbGpPWpGaD
Dolutegravir—Hypersensitivity—Prednisone—prostate cancer	0.00016	0.000552	CcSEcCtD
Dolutegravir—Rash—Docetaxel—prostate cancer	0.000158	0.000548	CcSEcCtD
Dolutegravir—Dermatitis—Docetaxel—prostate cancer	0.000158	0.000547	CcSEcCtD
Dolutegravir—Headache—Docetaxel—prostate cancer	0.000157	0.000544	CcSEcCtD
Dolutegravir—Asthenia—Prednisone—prostate cancer	0.000156	0.000538	CcSEcCtD
Dolutegravir—Vomiting—Capecitabine—prostate cancer	0.000155	0.000535	CcSEcCtD
Dolutegravir—Nervous system disorder—Doxorubicin—prostate cancer	0.000154	0.000532	CcSEcCtD
Dolutegravir—Rash—Capecitabine—prostate cancer	0.000153	0.00053	CcSEcCtD
Dolutegravir—Pruritus—Prednisone—prostate cancer	0.000153	0.00053	CcSEcCtD
Dolutegravir—Insomnia—Epirubicin—prostate cancer	0.000153	0.00053	CcSEcCtD
Dolutegravir—Dermatitis—Capecitabine—prostate cancer	0.000153	0.00053	CcSEcCtD
Dolutegravir—Headache—Capecitabine—prostate cancer	0.000152	0.000527	CcSEcCtD
Dolutegravir—Skin disorder—Doxorubicin—prostate cancer	0.000152	0.000527	CcSEcCtD
Dolutegravir—Nausea—Docetaxel—prostate cancer	0.000149	0.000516	CcSEcCtD
Dolutegravir—Diarrhoea—Prednisone—prostate cancer	0.000148	0.000513	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Epirubicin—prostate cancer	0.000146	0.000506	CcSEcCtD
Dolutegravir—Fatigue—Epirubicin—prostate cancer	0.000146	0.000505	CcSEcCtD
Dolutegravir—Nausea—Capecitabine—prostate cancer	0.000145	0.0005	CcSEcCtD
Dolutegravir—Dizziness—Prednisone—prostate cancer	0.000143	0.000496	CcSEcCtD
Dolutegravir—Insomnia—Doxorubicin—prostate cancer	0.000142	0.00049	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Epirubicin—prostate cancer	0.000139	0.000479	CcSEcCtD
Dolutegravir—Vomiting—Prednisone—prostate cancer	0.000138	0.000476	CcSEcCtD
Dolutegravir—Rash—Prednisone—prostate cancer	0.000137	0.000472	CcSEcCtD
Dolutegravir—Dermatitis—Prednisone—prostate cancer	0.000137	0.000472	CcSEcCtD
Dolutegravir—Headache—Prednisone—prostate cancer	0.000136	0.000469	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Doxorubicin—prostate cancer	0.000135	0.000468	CcSEcCtD
Dolutegravir—Fatigue—Doxorubicin—prostate cancer	0.000135	0.000468	CcSEcCtD
Dolutegravir—Abdominal pain—Epirubicin—prostate cancer	0.000134	0.000463	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—CBR1—prostate cancer	0.00013	0.000627	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—TST—prostate cancer	0.00013	0.000627	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GRHL1—prostate cancer	0.00013	0.000627	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PSAT1—prostate cancer	0.00013	0.000627	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CSAD—prostate cancer	0.00013	0.000627	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—ADI1—prostate cancer	0.00013	0.000627	CbGpPWpGaD
Dolutegravir—Nausea—Prednisone—prostate cancer	0.000129	0.000445	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Doxorubicin—prostate cancer	0.000128	0.000443	CcSEcCtD
Dolutegravir—Hypersensitivity—Epirubicin—prostate cancer	0.000125	0.000432	CcSEcCtD
Dolutegravir—Abdominal pain—Doxorubicin—prostate cancer	0.000124	0.000429	CcSEcCtD
Dolutegravir—Asthenia—Epirubicin—prostate cancer	0.000122	0.000421	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—UGT2B17—prostate cancer	0.000121	0.000583	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—UGT2B15—prostate cancer	0.000121	0.000583	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CKMT2—prostate cancer	0.000121	0.000583	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GRHPR—prostate cancer	0.000121	0.000583	CbGpPWpGaD
Dolutegravir—Pruritus—Epirubicin—prostate cancer	0.00012	0.000415	CcSEcCtD
Dolutegravir—Diarrhoea—Epirubicin—prostate cancer	0.000116	0.000401	CcSEcCtD
Dolutegravir—Hypersensitivity—Doxorubicin—prostate cancer	0.000116	0.0004	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—MBTPS1—prostate cancer	0.000114	0.000548	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—RFK—prostate cancer	0.000114	0.000548	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—AOX1—prostate cancer	0.000114	0.000548	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GSTM3—prostate cancer	0.000114	0.000548	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PGAM2—prostate cancer	0.000114	0.000548	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—NAGLU—prostate cancer	0.000114	0.000548	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—SULT2B1—prostate cancer	0.000114	0.000548	CbGpPWpGaD
Dolutegravir—Asthenia—Doxorubicin—prostate cancer	0.000113	0.000389	CcSEcCtD
Dolutegravir—Dizziness—Epirubicin—prostate cancer	0.000112	0.000388	CcSEcCtD
Dolutegravir—Pruritus—Doxorubicin—prostate cancer	0.000111	0.000384	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—AMACR—prostate cancer	0.000108	0.000519	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CYP3A43—prostate cancer	0.000108	0.000519	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—SRD5A2—prostate cancer	0.000108	0.000519	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—DEGS1—prostate cancer	0.000108	0.000519	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—NAT1—prostate cancer	0.000108	0.000519	CbGpPWpGaD
Dolutegravir—Vomiting—Epirubicin—prostate cancer	0.000108	0.000373	CcSEcCtD
Dolutegravir—Diarrhoea—Doxorubicin—prostate cancer	0.000107	0.000371	CcSEcCtD
Dolutegravir—Rash—Epirubicin—prostate cancer	0.000107	0.00037	CcSEcCtD
Dolutegravir—Dermatitis—Epirubicin—prostate cancer	0.000107	0.000369	CcSEcCtD
Dolutegravir—Headache—Epirubicin—prostate cancer	0.000106	0.000367	CcSEcCtD
Dolutegravir—Dizziness—Doxorubicin—prostate cancer	0.000104	0.000359	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—HSD17B1—prostate cancer	0.000103	0.000495	CbGpPWpGaD
Dolutegravir—Nausea—Epirubicin—prostate cancer	0.000101	0.000348	CcSEcCtD
Dolutegravir—Vomiting—Doxorubicin—prostate cancer	9.97e-05	0.000345	CcSEcCtD
Dolutegravir—Rash—Doxorubicin—prostate cancer	9.89e-05	0.000342	CcSEcCtD
Dolutegravir—Dermatitis—Doxorubicin—prostate cancer	9.88e-05	0.000342	CcSEcCtD
Dolutegravir—Headache—Doxorubicin—prostate cancer	9.83e-05	0.00034	CcSEcCtD
Dolutegravir—Nausea—Doxorubicin—prostate cancer	9.32e-05	0.000322	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—B4GALT4—prostate cancer	9.18e-05	0.000442	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—HPGD—prostate cancer	9.18e-05	0.000442	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—TNFRSF21—prostate cancer	8.63e-05	0.000415	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CYP7B1—prostate cancer	8.4e-05	0.000404	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—MTAP—prostate cancer	8.4e-05	0.000404	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—SULT1E1—prostate cancer	8.19e-05	0.000394	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—SRD5A1—prostate cancer	8.19e-05	0.000394	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—TGFB1—prostate cancer	7.94e-05	0.000382	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—ACSL4—prostate cancer	7.81e-05	0.000375	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—HSD17B3—prostate cancer	7.81e-05	0.000375	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PHGDH—prostate cancer	7.49e-05	0.00036	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—UMPS—prostate cancer	7.49e-05	0.00036	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—ARG2—prostate cancer	7.49e-05	0.00036	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—LDHB—prostate cancer	7.34e-05	0.000353	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CYP3A5—prostate cancer	7.21e-05	0.000347	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GSTA3—prostate cancer	6.96e-05	0.000335	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—UCP3—prostate cancer	6.96e-05	0.000335	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—TCN2—prostate cancer	6.96e-05	0.000335	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PDHA1—prostate cancer	6.96e-05	0.000335	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—HSD3B1—prostate cancer	6.64e-05	0.000319	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—SLC22A3—prostate cancer	6.64e-05	0.000319	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—TBXAS1—prostate cancer	6.37e-05	0.000306	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GSTA4—prostate cancer	6.37e-05	0.000306	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GSTA2—prostate cancer	6.2e-05	0.000298	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—SULT1A1—prostate cancer	6.13e-05	0.000295	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—ABCG5—prostate cancer	6.13e-05	0.000295	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GSTA1—prostate cancer	5.98e-05	0.000288	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—HSD3B2—prostate cancer	5.92e-05	0.000285	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GSTO1—prostate cancer	5.92e-05	0.000285	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—NAT2—prostate cancer	5.92e-05	0.000285	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CYP2C18—prostate cancer	5.67e-05	0.000273	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—LRP2—prostate cancer	5.67e-05	0.000273	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PLCB2—prostate cancer	5.67e-05	0.000273	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—P4HB—prostate cancer	5.56e-05	0.000268	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—SLC22A1—prostate cancer	5.41e-05	0.00026	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—SULT2A1—prostate cancer	5.27e-05	0.000254	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—MED12—prostate cancer	5.19e-05	0.00025	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GNG5—prostate cancer	5.15e-05	0.000248	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—NCOA3—prostate cancer	4.96e-05	0.000238	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—HPGDS—prostate cancer	4.73e-05	0.000227	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CYP2C19—prostate cancer	4.7e-05	0.000226	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GSTT1—prostate cancer	4.59e-05	0.000221	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—ACHE—prostate cancer	4.59e-05	0.000221	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CYP2A6—prostate cancer	4.54e-05	0.000218	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—AKR1C3—prostate cancer	4.41e-05	0.000212	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PRKACB—prostate cancer	4.39e-05	0.000211	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CYP17A1—prostate cancer	4.34e-05	0.000209	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—NCOA2—prostate cancer	4.14e-05	0.000199	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—SLC5A5—prostate cancer	3.95e-05	0.00019	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CYP2E1—prostate cancer	3.86e-05	0.000185	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—NQO1—prostate cancer	3.81e-05	0.000183	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—TH—prostate cancer	3.76e-05	0.000181	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CYP3A4—prostate cancer	3.72e-05	0.000179	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CYP1B1—prostate cancer	3.66e-05	0.000176	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GGT1—prostate cancer	3.54e-05	0.00017	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—NCOA1—prostate cancer	3.49e-05	0.000168	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CYP19A1—prostate cancer	3.44e-05	0.000165	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—RXRA—prostate cancer	3.32e-05	0.00016	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—COMT—prostate cancer	3.2e-05	0.000154	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GSTP1—prostate cancer	3.18e-05	0.000153	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—ITPR1—prostate cancer	3.13e-05	0.00015	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—TYMS—prostate cancer	2.96e-05	0.000142	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GSTM1—prostate cancer	2.92e-05	0.000141	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—LPL—prostate cancer	2.87e-05	0.000138	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CYP1A1—prostate cancer	2.77e-05	0.000133	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—ERCC2—prostate cancer	2.75e-05	0.000132	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—MTHFR—prostate cancer	2.58e-05	0.000124	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PPARA—prostate cancer	2.53e-05	0.000122	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CAV1—prostate cancer	2.38e-05	0.000115	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PIK3CG—prostate cancer	2.17e-05	0.000104	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—INS—prostate cancer	2.05e-05	9.88e-05	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CREBBP—prostate cancer	2.01e-05	9.68e-05	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PIK3CD—prostate cancer	1.91e-05	9.17e-05	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—NOS3—prostate cancer	1.8e-05	8.66e-05	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PIK3CB—prostate cancer	1.66e-05	8e-05	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PTGS2—prostate cancer	1.65e-05	7.92e-05	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PTEN—prostate cancer	1.44e-05	6.91e-05	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—EP300—prostate cancer	1.37e-05	6.59e-05	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PIK3CA—prostate cancer	1.01e-05	4.87e-05	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—AKT1—prostate cancer	8.28e-06	3.98e-05	CbGpPWpGaD
